Common genetic variants and risk for HPV persistence and progression to cervical cancer

PLoS ONE

Volumn 5, Issue 1, 2010, Pages

  Wang, Sophia S ^a,c   Gonzalez, Paula ^b   Yu, Kai ^c   Porras, Carolina ^b   Li, Qizhai ^c,d   Safaeian, Mahboobeh ^c   Rodriguez, Ana Cecilia ^b   Sherman, Mark E ^c   Bratti, Concepcion ^b   Schiffman, Mark ^c   Wacholder, Sholom ^c   Burk, Robert D ^e   Herrero, Rolando ^b   Chanock, Stephen J ^f   Hildesheim, Allan ^c  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b PROYECTO EPIDEMIOLÓGICO GUANACASTE   (Costa Rica)

^c NATIONAL CANCER INSTITUTE   (United States)

^d CHINESE ACADEMY OF SCIENCES   (China)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CARCINOGENESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DMC1 GENE; DNA REPAIR; DUT GENE; EVER1 GENE; EVER2 GENE; FEMALE; GENE; GENE REPLICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GTF2H4 GENE; HUMAN; IFNG GENE; MAJOR CLINICAL STUDY; OAS3 GENE; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; SULF1 GENE; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION; WART VIRUS;

ALPHAPAPILLOMAVIRUS; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS;

EID: 77952504856     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008667     Document Type: Article

References (20)

1. Castellsague X, Munoz N (2003) Chapter 3: Cofactors in human papillomavirus carcinogenesis-role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr. pp 20-28.
2. Magnusson PK, Lichtenstein P, Gyllensten UB (2000) Heritability of cervical tumours. Int J Cancer 88: 698-701.
3. Hildesheim A, Wang SS (2002) Host and viral genetics and risk of cervical cancer: a review. Virus Res 89: 229-240.
4. Wang SS, Hildesheim A (2003) Chapter 5: Viral and host factors in human papillomavirus persistence and progression. J Natl Cancer Inst Monogr. pp 35-40.
5. Wang SS, Bratti MC, Rodriguez AC, Herrero R, Burk RD, et al. (2009) Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer. J Infect Dis 199: 20-30.
6. Wood RD, Mitchell M, Lindahl T (2005) Human DNA repair genes, 2005. Mutat Res 577: 275-283.
7. Brehin AC, Casademont I, Frenkiel MP, Julier C, Sakuntabhai A, et al. (2009) The large form of human 2′,5′-Oligoadenylate Synthetase (OAS3) exerts antiviral effect against Chikungunya virus. Virology 384: 216-222.
8. Lamanna WC, Frese MA, Balleininger M, Dierks T (2008) Sulf loss influences N-, 2-O-, and 6-O-sulfation of multiple heparan sulfate proteoglycans and modulates fibroblast growth factor signaling. J Biol Chem 283: 27724-27735.
9. Johnson KM, Kines RC, Roberts JN, Lowy DR, Schiller JT, et al. (2009) Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. J Virol 83: 2067-2074.
10. Orth G (2008) Host defenses against human papillomaviruses: lessons from epidermodysplasia verruciformis. Curr Top Microbiol Immunol 321: 59-83.
11. Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, et al. (2000) Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 92: 464-474.
12. Herrero R, Schiffman MH, Bratti C, Hildesheim A, Balmaceda I, et al. (1997) Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project. Rev Panam Salud Publica 1: 362-375.
13. Schiffman M, Herrero R, Hildesheim A, Sherman ME, Bratti M, et al. (2000) HPV DNA testing in cervical cancer screening: results from women in a highrisk province of Costa Rica. JAMA 283: 87-93.
14. Herrero R, Castle PE, Schiffman M, Bratti MC, Hildesheim A, et al. (2005) Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 191: 1796-1807.
15. Packer BR, Yeager M, Burdett L, Welch R, Beerman M, et al. (2006) SNP500Cancer: a public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes. Nucl Acids Res 34: D617-D621.
16. Carlson CS, Eberle MA, Rieder MJ, Yi Q, et al. (2004) Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 74: 106-120.
17. Taylor J, Tibshirani R (2006) A tail strength measure for assessing the overall univariate significance in a dataset. Biostat 7: 167-181.
18. Yu K, Li Q, Bergen AW, Pfeiffer RM, Rosenberg PS, et al. (2009) Pathway analysis by adaptive combination of P-values. Genet Epidemiol.
19. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc B 57: 289-300.
20. Barrett J, Fry B, Maller J, Daly M (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265.